NCT06365814

Brief Summary

Background: Gastric cancer patients receiving neoadjuvant chemotherapy (NACT) are more vulnerable to perioperative stress. Enhanced recovery after surgery (ERAS) is widely used in surgical patients aiming at reducing stress responses. However, whether this approach is safe and feasible for gastric cancer patients received minimally invasive radical gastrectomy after NACT remained determined. So, the objective of this study is to investigate the effects of ERAS for this special group of gastric cancer patients. Materials and Methods: The data of gastric cancer patients who underwent minimally invasive radical gastrectomy after NACT were collected in this retrospective cohort study. Patients were divided into an ERAS group and a conventional group based on whether they received perioperative ERAS management. Propensity score matching was conducted to eliminate bias. Pre- and postoperative inflammatory and nutritional marker levels, postoperative complications, recovery indices and 3-year OS and RFS were observed.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
252

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2024

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

April 9, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 15, 2024

Completed
Last Updated

April 15, 2024

Status Verified

April 1, 2024

Enrollment Period

6 months

First QC Date

April 9, 2024

Last Update Submit

April 11, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • postoperative infectious complications

    The primary outcome was the incidence of postoperative infectious complications, which were defined as bacterial infections within 30 d after surgery. The diagnosis of infectious complications was based on fever (≥38°C), elevation of C-reactive protein (CRP), specific clinical symptoms of infection, and positive bacterial culture.

    up tp 30 days after surgery

Secondary Outcomes (4)

  • postoperative recovery parameter

    up tp 30 days after surgery

  • blood test result

    Postoperative, on postoperative day 1, 3 and 5

  • 3-year overall survival

    3 years

  • 3-years recurrence-free survival

    3 years

Study Arms (2)

ERAS group

Other: enhanced recovery after surgery

Conventional group

Other: conventional perioperative management

Interventions

ERAS is a comprehensive perioperative interventions, including preoperative patient education, prehabilitation, nutritional support, minimally invasive surgery and other methods, can reduce surgical stress and promote patient recovery

ERAS group

conventional perioperative management

Conventional group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

From January 2015 to October 2020, the data of 390 gastric cancer patients who underwent laparoscopic or robotic minimally invasive radical gastrectomy after NACT at the Department of Gastrointestinal Surgery, the Affiliated Hospital of Qingdao University, were collected and divided into ERAS group and conventional group according to whether they received perioperative ERAS pathway management.

You may qualify if:

  • gastric adenocarcinoma confirmed by histopathology,
  • received 2 to 4 cycles of NACT before surgery,
  • minimally invasive (DaVinci or laparoscopy) radical gastrectomy with D2 lymph node dissection

You may not qualify if:

  • conversion to open surgery due to intraoperative difficulties or uncontrolled complications (for example, intraoperative massive bleeding),
  • inability to complete the planned preoperative chemotherapy,
  • infeasibility of performing radical gastrectomy during surgery
  • ERAS item implementation rate less than 60%

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Gastrointestinal Surgery, Qingdao University Affiliated Hospital

Qingdao, Shandong, 266000, China

Location

MeSH Terms

Conditions

Stomach Neoplasms

Interventions

Enhanced Recovery After Surgery

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesStomach Diseases

Intervention Hierarchy (Ancestors)

Perioperative CareSurgical Procedures, Operative

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof.

Study Record Dates

First Submitted

April 9, 2024

First Posted

April 15, 2024

Study Start

October 1, 2023

Primary Completion

April 1, 2024

Study Completion

April 1, 2024

Last Updated

April 15, 2024

Record last verified: 2024-04

Locations